SCHEMBL29813201

SCHEMBL29813201

CCOC(=O)Nc1sc2c(F)ccc(Br)c2c1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 9/20 0.40
MEN1 O00255 8/20 0.40
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
RXFP1 Q9HBX9 1/20 0.39
HPGD P15428 4/20 0.39
BRAF P15056 3/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MCL1 Q07820 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23496853 1.00 ALDH1A1 (0.47) ALDH1A1NPC1RAB9AALOX15MAPK1
SCHEMBL24718536 0.89 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AALOX15MAPK1
SCHEMBL25643115 0.86 ALDH1A1 (0.47) ALDH1A1NPC1RAB9AALOX15MAPK1
SCHEMBL23496851 0.85 ALDH1A1 (0.38) ALDH1A1NPC1RAB9AMAPK1KMT2A
SCHEMBL30078401 0.85 ALDH1A1 (0.38) ALDH1A1NPC1RAB9AMAPK1KMT2A
SCHEMBL23498289 0.84 MEN1 (0.36) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL30781859 0.84 ALDH1A1 (0.47) ALDH1A1NPC1RAB9AALOX15MAPK1
SCHEMBL27100883 0.84 ALDH1A1 (0.47) ALDH1A1NPC1RAB9AALOX15MAPK1
SCHEMBL29812974 0.84 MEN1 (0.36) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL30014245 0.83 ALDH1A1 (0.47) ALDH1A1NPC1RAB9AALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083750-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC 2026-03-26 US disclosed
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 US disclosed
EP-4640684-A1 KRAS G12D INHIBITORS AND USES THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-10-29 EP disclosed
EP-4577214-A2 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS Merck Sharp & Dohme LLC (US) 2025-07-02 EP disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
CN-119894891-A KRAS G12D inhibitor and application thereof 上海和誉生物医药科技有限公司 2025-04-25 CN disclosed
WO-2025077663-A1 FUSED RING COMPOUND AND USE 成都海博为药业有限公司 2025-04-17 WO disclosed
WO-2025077770-A1 FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR 成都海博为药业有限公司 2025-04-17 WO disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed
EP-4436571-A1 SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS Merck Sharp & Dohme LLC (US) 2024-10-02 EP disclosed
WO-2024131827-A1 KRAS G12D INHIBITORS AND USES THEREOF 上海和誉生物医药科技有限公司 2024-06-27 WO disclosed
CN-117820333-A KRAS G12C inhibitors 伊莱利利公司 2024-04-05 CN disclosed
WO-2024044667-A2 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2024-02-29 WO disclosed
CN-117500799-A Substituted fused azines as KRAS G12D inhibitors 伊莱利利公司 2024-02-02 CN disclosed
CN-114828964-B KRAS G12C inhibitors 伊莱利利公司 2023-11-24 CN disclosed
WO-2023097227-A1 SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS MERCK SHARP & DOHME LLC (US) 2023-06-01 WO disclosed
CN-114828964-A KRAS G12C inhibitors 伊莱利利公司 2022-07-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS ALDH1A1 4071/4885NPC1 2198/4885RAB9A 96/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS ALDH1A1 3593/4885NPC1 3624/4885RAB9A 105/4885
US-20260083750-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS KRAS, NRAS, RASGRP1 ALDH1A1 3539/4885NPC1 2120/4885RAB9A 16/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS ALDH1A1 1854/4885NPC1 1122/4885RAB9A 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.